提示性公告 证券代码：301033 证券简称：迈普医学 公告编号：2026-005 广州迈普再生医学科技股份有限公司 关于持股 5%以上股东权益变动触及 1%的提示性公告 | 深圳市凯盈科技有限公司保证向本公司提供的信息内容真实、准确和完整， | | --- | | 没有虚假记载、误导性陈述或重大遗漏。 | | 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 | 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2025 年 12 月 12 日披露了《关于公司持股 5%以上股东减持股份的预 披露公告》（公告编号：2025-100），持股 5%以上股东深圳市凯盈 科技有限公司（以下简称"深圳凯盈"）计划在该公告披露日起 15 个交易日后的 3 个月内，通过集中竞价交易方式减持公司股份不超过 150,000 股，占公司总股本的 0.2237%（占剔除公司回购专用账户股 份数量后总股本的 0.2245%）。 本次变动是否为履行已作出 的承诺、意向、计划 是☑ 否□ 2025 年 12 月 12 日公司披露了《关于公司持股 5%以上股东减持 股份的预披露公告》（公告编号：2025-100）， ...

Group 1: Shareholder Reductions - Shangle Electronics' actual controller plans to reduce holdings by no more than 3% [1] - Yilian Technology's shareholder Changjiang Chenda intends to reduce holdings by no more than 2% [1] - Fuhuan Micro's actual controller's concerted actor plans to reduce holdings by no more than 1.93% [1] - Xueda Education's shareholder Nanjing Xingnaheyuan intends to reduce holdings by no more than 0.5% [1] - Maipu Medical's shareholder Tang Ying plans to reduce holdings by no more than 1.2541% [1] - Gaohua Technology's shareholder Huang Biao intends to reduce holdings by no more than 1.8 million shares [1] - Jindan Technology's shareholder Shouzhong Education plans to reduce holdings by no more than 3% [1] - Changjiang Communication's shareholders Wuhan Jinkong, New Energy Industry, and Wuhan Changfa plan to collectively reduce holdings by no more than 1% [1] - Jingce Electronics' shareholder Chen Kai intends to reduce holdings by no more than 1.79% [1] - Wuxi Zhenhua's shareholders Wuxi Junrui and its concerted actors plan to collectively reduce holdings by no more than 3% [1] - China Unicom's structural adjustment fund has cumulatively reduced holdings by 1.0764% [1] - Luxin Investment's controlling shareholder Luxin Group has reduced holdings by 1% [1] Group 2: Other Corporate Actions - Naipu Mining has terminated the subscription for equity in Swiss Veritas Resources AG [1] - Jiangyan Group's Ningbo Longji plans to reduce holdings by no more than 3% [1]

格隆汇2月3日丨迈普医学(301033.SZ)公布，因个人资金安排需要，唐莹女士计划通过集中竞价交易及 大宗交易方式减持公司股份不超过840,877股，占公司总股本的1.2541%（占剔除公司回购专用证券账户 股份数量后总股本的1.2587%）。减持期间为自本公告披露之日起15个交易日后的3个月内。 ...

迈普医学(301033.SZ)公告，公司股东唐莹女士计划通过集中竞价交易及大宗交易方式减持公司股份不 超过84.09万股，占公司总股本的1.2541%。减持期间为自本公告披露之日起15个交易日后的3个月内。 ...

Group 1 - The core point of the article is that the shareholder, Ms. Tang Ying, plans to reduce her stake in Maipu Medical (301033.SZ) by up to 840,900 shares, which represents 1.2541% of the company's total share capital [1] - The reduction will occur through centralized bidding and block trading methods [1] - The period for the share reduction is set to begin 15 trading days after the announcement and will last for three months [1]

南财智讯2月3日电，迈普医学公告，公司股东唐莹女士因个人资金安排需要，计划通过集中竞价交易及 大宗交易方式减持公司股份不超过840,877股，占公司总股本的1.2541%（占剔除公司回购专用证券账户 股份数量后总股本的1.2587%），减持期间为自本公告披露之日起15个交易日后的3个月内。 ...

迈普医学公告，截至披露日，股东唐莹持有公司股份84.09万股，占总股本1.2541%。因个人资金安排， 唐莹拟自公告披露之日起15个交易日后的3个月内，通过集中竞价交易减持不超67.05万股、通过大宗交 易减持不超17.04万股，合计不超84.09万股，占公司总股本1.2541%（占剔除公司回购专用证券账户股 份数量后总股本1.2587%）。唐莹与一致行动人叶涛合计持股231.09万股，占总股本3.4465%。 ...

特别提示： 1、截至本公告披露日，公司股东唐莹女士持有公司股份 840,877 股，占总 股本的 1.2541%。 广州迈普再生医学科技股份有限公司 关于公司股东减持股份的预披露公告 公司股东唐莹女士保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 预披露公告 证券代码：301033 证券简称：迈普医学 公告编号：2026-004 2、因个人资金安排需要，唐莹女士计划通过集中竞价交易及大宗交易方式 减持公司股份不超过 840,877 股，占公司总股本的 1.2541%（占剔除公司回购专 用证券账户股份数量后总股本的 1.2587%）。减持期间为自本公告披露之日起 15 个交易日后的 3 个月内。 注 3：上述持股比例以当前公司总股本 67,049,620 股（含回购专用证券账 户持有的 241,783 股股份）为计算基准。 二、 唐莹女士减持计划的主要内容 公司于近日收到公司股东唐莹女士出具的《关于计划减持股份的 告知函》，现将有关情况公告如下： 一、 减持主体的基本情况 | 股东名称 | 股东身份 | 持股 ...

Core Viewpoint - The article discusses the recent advancements in the use of PEEK (Polyether Ether Ketone) materials in neurosurgery, highlighting its endorsement in the latest expert consensus and the impact of policy changes on market accessibility [3][6][8]. Group 1: Expert Consensus and Material Endorsement - The "Expert Consensus on Cranioplasty" published in August 2025 recommends PEEK as a primary material for cranioplasty, marking a significant update in clinical application standards [3][6]. - PEEK's mechanical properties closely resemble natural bone, providing excellent stability and biocompatibility, which facilitates postoperative assessments [7]. Group 2: Market Dynamics and Policy Impact - The application history of PEEK in neurosurgery reflects the development trajectory of China's high-end medical materials market, with its initial use in aerospace before entering the medical implant sector [9]. - Despite its superior performance, PEEK faced market penetration challenges due to its high cost compared to traditional titanium mesh, limiting its accessibility to a select group of patients [9]. - Recent international procurement and healthcare reform policies have begun to lower the end-user prices of PEEK products, improving clinical accessibility and allowing more patients to benefit from high-performance materials [9]. Group 3: Innovative Solutions and Product Development - Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. has launched the SAILU® craniofacial repair system, which integrates PEEK materials and a comprehensive service system based on a decade of customization experience [10]. - The SAILU® product design addresses clinical needs with features that enhance surgical efficiency and adaptability, particularly for pediatric patients [12]. - Maipu has expanded its product line to include the Luchang® hydrophilic coating cranial drainage kit, which has been included in the provincial alliance procurement directory, showcasing ongoing innovation in neurosurgical products [16][18]. Group 4: Future Trends and Market Transformation - The endorsement of PEEK materials in the new expert consensus and the steady progress of provincial alliance procurement are driving a shift towards a performance-first, value-oriented model in the high-value consumables market for neurosurgery [18]. - The collaboration between advancements in material science and healthcare policies is systematically improving treatment pathways and outcomes for patients with cranial defects [18].

Market Overview - The medical device sector experienced a decline of 1.98% on February 2, with Hai Li Biological leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Top Performers - Mai Pu Medical (301033) saw a closing price of 73.70, with an increase of 8.35% and a trading volume of 31,100 shares, totaling 223 million yuan [1] - Nanwei Co., Ltd. (603880) closed at 6.63, up 5.41%, with a trading volume of 191,200 shares, amounting to 126 million yuan [1] - Gongdong Medical (605369) closed at 19.46, up 2.91%, with a trading volume of 44,800 shares, totaling 86.97 million yuan [1] Underperformers - Hai Li Biological (603718) closed at 5.84, down 10.02%, with a trading volume of 84,500 shares, totaling 49.32 million yuan [2] - Yuanmei Medical (002950) closed at 10.46, down 9.52%, with a trading volume of 255,000 shares, amounting to 269 million yuan [2] - Yikang Technology (688301) closed at 111.34, down 5.92%, with a trading volume of 44,200 shares, totaling 503 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 533 million yuan from institutional investors, while retail investors experienced a net inflow of 174 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors showed interest [2] Individual Stock Capital Flow - Sino Medical (688108) had a net inflow of 46.28 million yuan from institutional investors, while retail investors saw a net outflow of 58.30 million yuan [3] - Mai Pu Medical (301033) experienced a net inflow of 29.68 million yuan from institutional investors, with a net outflow of 34.84 million yuan from retail investors [3] - Gongdong Medical (605369) had a net inflow of 13.18 million yuan from institutional investors, while retail investors faced a net outflow of 9.00 million yuan [3]